COVID-19-related mortality in cancer patients in an Irish setting.
COVID-19
Cancer
Chemotherapy
Malignancy
Mortality
SARS CoV-2
Journal
Irish journal of medical science
ISSN: 1863-4362
Titre abrégé: Ir J Med Sci
Pays: Ireland
ID NLM: 7806864
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
05
02
2021
accepted:
18
09
2021
pubmed:
27
10
2021
medline:
24
9
2022
entrez:
26
10
2021
Statut:
ppublish
Résumé
The COVID-19 pandemic has impacted significantly on healthcare across the globe. It has been reported to have higher incidence and be associated with worse outcomes in patients with cancer. To examine the characteristics of patients with cancer who were diagnosed with COVID-19 and to identify factors which may predict a poorer outcome. Patients attending oncology services in Beaumont Hospital who were diagnosed with COVID-19 between March and May 2020 were included. Demographics and outcomes were determined by chart review. Twenty-seven patients were included in the study. The median age was 62; 59% were male. Ten patients (37%) died all of whom had metastatic or incurable locally advanced disease. Patients with lung cancer had a higher rate of COVID-19 and poorer outcomes. Those with a performance status (PS) ≥ 3 were more likely to die than those with PS ≤ 2. Compared to those who recovered, patients who died had a higher number of organs affected by cancer and a higher mean Palliative Prognostic Score. Patients attending oncology services during the initial phase of the COVID-19 pandemic had an increased rate of SARS-CoV-2 infection and a higher mortality rate than the general population. Those who died had more advanced cancer as demonstrated by poorer performance status, a greater burden of metastatic disease and a higher Palliative Prognostic Score.
Sections du résumé
BACKGROUND
BACKGROUND
The COVID-19 pandemic has impacted significantly on healthcare across the globe. It has been reported to have higher incidence and be associated with worse outcomes in patients with cancer.
AIM
OBJECTIVE
To examine the characteristics of patients with cancer who were diagnosed with COVID-19 and to identify factors which may predict a poorer outcome.
METHODS
METHODS
Patients attending oncology services in Beaumont Hospital who were diagnosed with COVID-19 between March and May 2020 were included. Demographics and outcomes were determined by chart review.
RESULTS
RESULTS
Twenty-seven patients were included in the study. The median age was 62; 59% were male. Ten patients (37%) died all of whom had metastatic or incurable locally advanced disease. Patients with lung cancer had a higher rate of COVID-19 and poorer outcomes. Those with a performance status (PS) ≥ 3 were more likely to die than those with PS ≤ 2. Compared to those who recovered, patients who died had a higher number of organs affected by cancer and a higher mean Palliative Prognostic Score.
CONCLUSION
CONCLUSIONS
Patients attending oncology services during the initial phase of the COVID-19 pandemic had an increased rate of SARS-CoV-2 infection and a higher mortality rate than the general population. Those who died had more advanced cancer as demonstrated by poorer performance status, a greater burden of metastatic disease and a higher Palliative Prognostic Score.
Identifiants
pubmed: 34697787
doi: 10.1007/s11845-021-02815-9
pii: 10.1007/s11845-021-02815-9
pmc: PMC8545357
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2013-2018Informations de copyright
© 2021. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland.
Références
Liang W, Guan W, Chen R et al (2020) Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. https://doi.org/10.1016/S1470-2045(20)30096-6
doi: 10.1016/S1470-2045(20)30096-6
pubmed: 32791048
pmcid: 7159000
Kuderer NM, Choueiri TK, Shah DP et al (2020) Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. https://doi.org/10.1016/S0140-6736(20)31187-9
doi: 10.1016/S0140-6736(20)31187-9
pubmed: 33038964
pmcid: 7544437
Lee LYW, Cazier JB, Starkey T (2020) COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. https://doi.org/10.1016/S0140-6736(20)31173-9
doi: 10.1016/S0140-6736(20)31173-9
pubmed: 33347812
pmcid: 7836843
Maltoni M, Nanni O, Pirovano M et al (1999) Successful validation of the palliative prognostic score in terminally ill cancer patients. J Pain Symptom Manage. https://doi.org/10.1016/S0885-3924(98)00146-8
doi: 10.1016/S0885-3924(98)00146-8
pubmed: 10203876
Bertuzzi AF, Marrari A, Gennaro N et al (2020) Low incidence of sars-cov-2 in patients with solid tumours on active treatment: an observational study at a tertiary cancer centre in lombardy. Italy Cancers (Basel). https://doi.org/10.3390/cancers12092352
doi: 10.3390/cancers12092352
Rogado J, Obispo B, Pangua C et al (2020) Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid. Clin Transl Oncol. https://doi.org/10.1007/s12094-020-02381-z
doi: 10.1007/s12094-020-02381-z
pubmed: 32449128
pmcid: 7246222
Yu J, Ouyang W, Chua MLK, Xie C (2020) SARS-CoV-2 Transmission in patients with cancer at a Tertiary Care Hospital in Wuhan. China JAMA Oncol. https://doi.org/10.1001/jamaoncol.2020.0980
doi: 10.1001/jamaoncol.2020.0980
pubmed: 32970130
Zhang L, Zhu F, Xie L et al (2020) Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan. China Ann Oncol. https://doi.org/10.1016/j.annonc.2020.03.296
doi: 10.1016/j.annonc.2020.03.296
pubmed: 33188874
Jee J, Foote MB, Lumish M et al (2020) Chemotherapy and COVID-19 outcomes in patients with cancer. J Clin Oncol. https://doi.org/10.1200/jco.20.01307
doi: 10.1200/jco.20.01307
pubmed: 32795225
pmcid: 7571792
Dai M-Y, Liu D, Liu M et al (2020) Patients with Cancer appear more vulnerable to SARS-CoV-2: a multi-center study during the COVID-19 outbreak. SSRN Electron J. https://doi.org/10.2139/ssrn.3558017
doi: 10.2139/ssrn.3558017
Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease (COVID-19) outbreak in China. JAMA. https://doi.org/10.1001/jama.2020.2648
Petrilli CM, Jones SA, Yang J et al (2020) Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease, in New York City: Prospective cohort study. BMJ. https://doi.org/10.1136/bmj.m1966
Chow N, Fleming-Dutra K, Gierke R et al (2020) Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 — United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep 2020. https://doi.org/10.15585/mmwr.mm6913e2
Zhang H, Wang L, Chen Y et al (2020) Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan. China Cancer 126:4023–4031. https://doi.org/10.1002/cncr.33042
doi: 10.1002/cncr.33042
pubmed: 32573776
Yang K, Sheng Y, Huang C et al (2020) Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. https://doi.org/10.1016/S1470-2045(20)30310-7
doi: 10.1016/S1470-2045(20)30310-7
pubmed: 33271114
pmcid: 8427481